64 related articles for article (PubMed ID: 7972221)
1. Ha-ras p21 in neuroblastoma: a new marker in prediction of patient outcome.
Tanaka T
Prog Clin Biol Res; 1994; 385():275-80. PubMed ID: 7972221
[No Abstract] [Full Text] [Related]
2. [Tumor markers--personal experience. Ha-ras P21 in neuroblastoma: a new marker associating to patient's prognosis].
Tanaka T
Gan To Kagaku Ryoho; 1991 Jan; 18(1):143-50. PubMed ID: 1987897
[TBL] [Abstract][Full Text] [Related]
3. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.
Tanaka T; Seeger RC; Tanabe M; Hiyama E; Shimoda H; Ida N
Cancer Detect Prev; 1994; 18(4):283-9. PubMed ID: 7982238
[TBL] [Abstract][Full Text] [Related]
4. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
5. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis.
Nakada K; Fujioka T; Kitagawa H; Takakuwa T; Yamate N
Jpn J Clin Oncol; 1993 Jun; 23(3):149-55. PubMed ID: 8350488
[TBL] [Abstract][Full Text] [Related]
6. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
7. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases.
Tanaka T; Slamon DJ; Shimada H; Shimoda H; Fujisawa T; Ida N; Seeger RC
Cancer; 1991 Sep; 68(6):1296-302. PubMed ID: 1873783
[TBL] [Abstract][Full Text] [Related]
8. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G
Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
[TBL] [Abstract][Full Text] [Related]
9. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.
Tanaka T; Slamon DJ; Shimoda H; Waki C; Kawaguchi Y; Tanaka Y; Ida N
Cancer Res; 1988 Feb; 48(4):1030-4. PubMed ID: 3276397
[TBL] [Abstract][Full Text] [Related]
10. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
11. N-myc amplification and cell proliferation rate in human neuroblastoma.
Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G
J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991
[TBL] [Abstract][Full Text] [Related]
12. Expression of type I interferon receptor and its relation with other prognostic factors in human neuroblastoma.
Mejía C; Navarro S; Colamonici OR; Pellín A; Castel V; Llombart-Bosch A
Oncol Rep; 1999; 6(1):149-53. PubMed ID: 9864419
[TBL] [Abstract][Full Text] [Related]
13. Multifocal neuroblastoma: biologic behavior and surgical aspects.
Hiyama E; Yokoyama T; Hiyama K; Yamaoka H; Matsuura Y; Nishimura Si; Ueda K
Cancer; 2000 Apr; 88(8):1955-63. PubMed ID: 10760774
[TBL] [Abstract][Full Text] [Related]
14. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Nagasaki A; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Eguchi H; Tsuneyoshi M
J Pediatr Surg; 2000 Dec; 35(12):1737-41. PubMed ID: 11101726
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
16. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.
Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M
Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322
[TBL] [Abstract][Full Text] [Related]
17. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
18. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
[TBL] [Abstract][Full Text] [Related]
19. [Limitations in the histopathologic diagnosis and prognosis of neuroblastoma].
Mihăilă D; Aprodu G; Ionescu C; Miron I; Maxim E; Plămădeală P
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):834-40. PubMed ID: 14756030
[TBL] [Abstract][Full Text] [Related]
20. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
